TARO-ADAPALENE/BENZOYL PEROXIDE FORTE 0.3 %
ADAPALENE : 0.3 % BENZOYL PEROXIDE : 2.5 % · DIN 02505053 · TARO PHARMACEUTICALS INC
Health Canada status: MARKETED
What is TARO-ADAPALENE/BENZOYL PEROXIDE FORTE?
TARO-ADAPALENE/BENZOYL PEROXIDE FORTE 0.3 % contains ADAPALENE : 0.3 % BENZOYL PEROXIDE : 2.5 %. It is listed in the Health Canada Drug Product Database under DIN 02505053, held by TARO PHARMACEUTICALS INC, supplied as GEL for TOPICAL administration. Health Canada currently lists it as marketed, status dated 24-Jan-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-ADAPALENE/BENZOYL PEROXIDE FORTE used for?
Taro - Adapalene / Benzoyl Peroxide Topical Gel is indicated for: Treatment of mild and moderate acne vulgaris, characterized by comedones, inflammatory papules/pustules in patients 9 years of age and older. Taro - Adapalene / Benzoyl Peroxide Forte Topical Gel is indicated for: Treatment of moderate and severe acne vulgaris, characterized by comedones, inflammatory papules/pustules with or without occasional nodules in patients 12 years of age and older.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02505053 |
|---|---|
| Brand name | TARO-ADAPALENE/BENZOYL PEROXIDE FORTE |
| Generic / active ingredient | ADAPALENE : 0.3 % BENZOYL PEROXIDE : 2.5 % |
| Manufacturer | TARO PHARMACEUTICALS INC |
| Strength | 0.3 % |
| Dosage form | GEL |
| Route of administration | TOPICAL |
| Schedule | Prescription |
| ATC code | D10AD53 ADAPALENE, COMBINATIONS |
| AHFS class | 84:92.00 ; 84:28.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jan-2022 |
| Original market date | 2022-01-24 00:00:00 |
How is it stored and handled?
null
How is it supplied?
null
What can be used instead?
Other Canadian products sharing ATC code D10AD53 ADAPALENE, COMBINATIONS. 6 of 6 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| SANDOZ ADAPALENE / BENZOYL PEROXIDE | 0.1 % | GEL | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02489007 |
| SANDOZ ADAPALENE / BENZOYL PEROXIDE FORTE | 2.5 % | GEL | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02517205 |
| TACTUPUMP | 0.1 % | GEL | GALDERMA CANADA INC | MARKETED | DIN 02365871 |
| TACTUPUMP FORTE | 2.5 % | GEL | GALDERMA CANADA INC | MARKETED | DIN 02446235 |
| TARO-ADAPALENE/BENZOYL PEROXIDE | 0.1 % | GEL | TARO PHARMACEUTICALS INC | MARKETED | DIN 02456923 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.